Latest CRISPR Therapeutics News & Updates

See the latest news and media coverage for CRISPR Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

CRISPR Therapeutics

Biotechnology company developing gene-based medicines

crisprtx.com

Headquarters: Boston, United States
Founded year: 2013
Company type: Public company
Number of employees: 300–500
Industry: Pharmaceuticals

Last updated Today

Latest news about CRISPR Therapeutics

In short: CRISPR Therapeutics reported strong Q2 2026 growth, secured expanded FDA approval for Casgevy, and advanced its in vivo clinical pipeline.

Company announcements

August 3 CRISPR Therapeutics

CRISPR Therapeutics reports second quarter 2026 financial results

CASGEVY revenue grew 151% year-over-year, FDA approved it for children as young as 2, and Phase 1 trials for CTX340 and CTX460 were initiated.

July 2 CRISPR Therapeutics

CRISPR Therapeutics expands FDA approval for young children

It is the first gene-edited therapy approved for children this young, covering both sickle cell disease and beta thalassemia.

May 4 CRISPR Therapeutics

CRISPR Therapeutics reported Q1 2026 financial results and business update

Revenue included $43M from CASGEVY, cash increased to $2.44B, and development milestones advanced across pipeline.

March 10 CRISPR Therapeutics

CRISPR Therapeutics announces proposed $350M convertible senior notes offering

The notes due 2031 will be offered to qualified institutional buyers in a private offering.

Media coverage

August 31 The Globe and Mail

Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ)

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

August 28 The New York Times

An Experimental Single-Time Treatment Slashed Cholesterol for a Year

A small gene-editing study significantly reduced LDL cholesterol levels, and the results have stuck...

August 12 MSN

Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli

The CRISPR therapy, SNIPR001, was administered following a single-patient emergency investigational new drug application.

August 6 The Stock Observer

Equities Analysts Offer Predictions for CRSP Q3 Earnings - Stock Observer

CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Research analysts at Brookline Capital Markets lifted their Q3 2026 EPS estimates for shares of CRISPR Therapeutics...

Never miss news about CRISPR Therapeutics

Track CRISPR Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

CRISPR Therapeutics competitors & trending companies

Browse news for competitors to CRISPR Therapeutics and other trending companies.